Department of Obstetrics and Gynecology, University Hospital Center Zagreb, Zagreb, Croatia.
Department of Women and Children's Health, University of Padua, Padua, Italy.
Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):553-558. doi: 10.1080/14737167.2021.1910026. Epub 2021 Mar 31.
: To study the impact of biosimilars in assisted reproductive treatments, we performed a review of the literature. Biosimilars are a bioequivalent chemical drug referred to the original. Their production is strongly requested in order to reduce drug cost and reduce health economic impact on national health system. In assisted reproductive treatments different gonadotropin biosimilars are being produced.: For this reason, we performed a review of the literature on follitropin alfa Gonal-F biosimilar, Ovaleap and Bemfola, to assess their cost efficacy in national health system. Cost effective (CE) analysis and incremental cost-effectiveness ratio (ICER) were used as parameters for biosimilar impact evaluation in the national health system economy. In particular, they had only slight impact on cost reduction of recombinant follitropin alfa products in Europe.: considering cost-effective analysis, Gonal-F remains the first choice for national health systems. However, well-designed powered methods are strongly needed to assess biosimilars cost-effectiveness.
为了研究生物类似药在辅助生殖治疗中的影响，我们对文献进行了回顾。生物类似药是指与原研药生物等效的化学药物。为了降低药物成本并减轻国家卫生系统的健康经济影响，强烈要求生产生物类似药。在辅助生殖治疗中，正在生产不同的促性腺激素生物类似药：为此，我们对卵泡刺激素阿尔法 Gonal-F 生物类似药、Ovaleap 和 Bemfola 的文献进行了回顾，以评估它们在国家卫生系统中的成本效益。成本效益分析（CE）和增量成本效益比（ICER）被用作评估生物类似药对国家卫生系统经济影响的参数。特别是，它们对欧洲重组卵泡刺激素阿尔法产品的成本降低影响很小。：从成本效益分析的角度来看，Gonal-F 仍然是国家卫生系统的首选。然而，强烈需要设计良好的有力方法来评估生物类似药的成本效益。
